These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 29697386)

  • 1. USE OF CIRCULATING TUMOR DNA FOR DETECTION OF BRAF V600E MUTATION AND TREATMENT MONITORING IN MELANOMA PATIENTS.
    Shapochka D; Shapochka T; Seleznyov O; Matveeva A; Dudin V
    Georgian Med News; 2018 Mar; (276):76-81. PubMed ID: 29697386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of the BRAF
    Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
    Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
    Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES
    Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.
    Schreuer M; Meersseman G; Van Den Herrewegen S; Jansen Y; Chevolet I; Bott A; Wilgenhof S; Seremet T; Jacobs B; Buyl R; Maertens G; Neyns B
    J Transl Med; 2016 Apr; 14():95. PubMed ID: 27095081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
    Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
    J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients.
    Pinzani P; Salvianti F; Cascella R; Massi D; De Giorgi V; Pazzagli M; Orlando C
    Clin Chim Acta; 2010 Sep; 411(17-18):1319-24. PubMed ID: 20576522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients.
    Emelyanova MA; Telysheva EN; Orlova KV; Ryabaya OO; Snigiryova GP; Abramov IS; Mikhailovich VM
    Cancer Genet; 2021 Jan; 250-251():25-35. PubMed ID: 33249369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
    Ashida A; Sakaizawa K; Uhara H; Okuyama R
    Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
    Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
    J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma.
    Polivka J; Gouda MA; Sharif M; Pesta M; Huang H; Treskova I; Woznica V; Windrichova J; Houfkova K; Kucera R; Fikrle T; Ricar J; Pivovarcikova K; Topolcan O; Janku F
    Cancer Med; 2024 Oct; 13(19):e70313. PubMed ID: 39387479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
    Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
    Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
    Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
    Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.
    Tsao SC; Weiss J; Hudson C; Christophi C; Cebon J; Behren A; Dobrovic A
    Sci Rep; 2015 Jun; 5():11198. PubMed ID: 26095797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.
    Haselmann V; Gebhardt C; Brechtel I; Duda A; Czerwinski C; Sucker A; Holland-Letz T; Utikal J; Schadendorf D; Neumaier M
    Clin Chem; 2018 May; 64(5):830-842. PubMed ID: 29483107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
    Yaman B; Kandiloğlu G; Akalin T
    Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
    Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
    Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.